Comparison · NCT02534844-86aba8e3
Adrabetadex vs Sham Control: Parts A/ B: Number of Participants Classified as CGIC Responders at Week 52
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Adrabetadex vs Sham Control: Parts A/ B: Number of Participants Classified as CGIC Responders at Week 52. Trial comparisons, record NCT02534844-86aba8e3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02534844-86aba8e3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.605 | 0.447 | 0.744 | wilson | |
| Risk in group 2 | 0.389 | 0.203 | 0.614 | wilson | |
| Risk difference, group 1 minus group 2 | 0.216 | -0.0585 | 0.448 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.56 | 0.826 | 2.93 | log | |
| Odds ratio, group 1 over group 2 | 2.41 | 0.763 | 7.61 | log | |
| Number needed to treat, for one more participant with the outcome on Adrabetadex than on Sham Control | 4.62 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: sham.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Adrabetadex | Participants received lumbar IT infusions of adrabetadex once every 2 weeks for a total of 52 weeks.. | 23 | 38 | OG001 |
| Group 2 | Sham Control | Participants received sham control procedures once every 2 weeks for a total of 52 weeks. | 7 | 18 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Parts A/ B: Number of Participants Classified as CGIC Responders at Week 52
- Description
The Clinician CGIC is a 7-point Likert scale. The scale requires assessment of change from a baseline level of disease activity, with anchors ranging from markedly improved, moderately improved, and minimally improved to no change and corresponding worsening (minimally, moderately, markedly). The Investigator rates his/her impression of the change in each participant's condition at week 52 on a scale from marked improvement (1) to marked worsening (7). CGIC Responders are defined as participants who received the caregiver's rating of no change, minimally improved, moderately improved, or markedly improved from baseline to Week 52.
- Time frame
- Week 52
- Population
mITT population included all randomized participants who received at least one treatment (sham or adrabetadex). As per planned analysis, efficacy data were collected and presented by overall randomized treatment assignment (either sham or adrabetadex). These two treatment arms (either sham or adrabetadex) combine data from Parts A and B of the study.
Source ClinicalTrials.gov
Trial
- Title
- VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
- NCT number
- NCT02534844
- Phases
- PHASE2, PHASE3
- Conditions
- Niemann-Pick Disease, Type C
- Interventions
- Parts A/B: Adrabetadex, Parts A/B: Sham Control
- Lead sponsor
- Mandos LLC
- Results first posted
- 2023-02-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02534844?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02534844-86aba8e3